Skip to main content
. 2020 Aug 19;2020:8813535. doi: 10.1155/2020/8813535

Figure 5.

Figure 5

The relationship between the serum occludin level and the clinical outcomes in patients with brain tumors. (a) Comparison of National Institutes of Health Stroke Scale (NIHSS) and Glasgow Coma Scale (GCS) scores at admission between patients with a preoperative occludin level < 3.015 ng/mL (n = 40) and those with a preoperative occludin level ≥ 3.015 ng/mL (n = 15). (b) Comparison of the incidences of preoperative severe brain edema and intracranial hemorrhage between patients with a preoperative occludin level < 3.015 ng/mL (n = 40) and those with a preoperative occludin level ≥ 3.015 ng/mL (n = 15). (c) Comparison of NIHSS and GCS scores at 1 day after surgery between patients with a postoperative occludin level < 3.033 ng/mL (n = 44) and those with a postoperative occludin level ≥ 3.033 ng/mL (n = 11). (d) Comparison of the incidences of postoperative severe brain edema and intracranial hemorrhage between patients with a postoperative occludin level < 3.033 ng/mL (n = 44) and those with a postoperative occludin level ≥ 3.033 ng/mL (n = 11).